PDCD1 and cancer: These universal gene expression programs may account for the widespread application of immunotherapy (e.g., PD-1/PD-L1 inhibitors and CTLA4 inhibitors) in a variety of cancers, in contrast to the targeted therapy which has limited indications in specific cancer types.